rially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Investor Contacts:BPC Financial Marketing
WaferGen Bio-systems, Inc.
510-780-2395WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations (Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012Revenue:Product
269,999License and royalty125,000—333,333—Total Revenue389,547176,608814,282269,999Cost of product revenue192,814144,327335,182245,322Gross profit196,73332,281479,10024,677Operating expenses:Sales and marketing625,390124,6921,577,317537,523Research and development1,581,4491,237,6174,246,7964,855,341General and administrative1,217,899521,9012,443,3172,406,171Total operating expenses3,424,7381,884,2108,267,4307,799,035Operating loss(3,228,005)(1,851,929)(7,788,330)(7,774,358)Other income
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE WaferGen Bio-systems, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy2
. WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference3
. WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 20124
. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment5
. WaferGen Bio-systems Awarded 1 Million Euro Grant by the Luxembourg Government to expand its European Operations6
. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center7
. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan8
. WaferGen Partners with Salk Institute to Establish a Nano-qPCR Core Lab9
. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs10
. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 201111
. Interleukin Genetics Reports Third Quarter 2011 Financial Results